Dabigatran-13C,d3 manufacturers
|
| | Dabigatran-13C,d3 Basic information |
| | Dabigatran-13C,d3 Chemical Properties |
| solubility | Acidic solution: soluble
DMSO: 0.5 mg/ml (@*25°C ) |
| | Dabigatran-13C,d3 Usage And Synthesis |
| Description | Dabigatran-13C-d3 is intended for use as an internal standard for the quantification of dabigatran (Item No. 17133) by GC- or LC-MS. Dabigatran is an inhibitor of thrombin (Ki = 0.0045 µM) and an active metabolite of the thrombin inhibitor prodrug dabigatran etexilate (Item No. 17131).1,2 It also inhibits trypsin (Ki = 0.0503 µM) but is selective for thrombin and trypsin over plasmin, Factor Xa, activated protein C, and tissue plasminogen activator (tPA; Kis = 1.695, 3.76, 20.93, and 45.36 µM, respectively).1WARNING This product is not for human or veterinary use. | | References | [1] NORBERT H. HAUEL. Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors[J]. Journal of Medicinal Chemistry, 2002, 45 9: 1757-1766. DOI: 10.1021/jm0109513
[2] WOLFGANG G EISERT. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30 10: 1885-1889. DOI: 10.1161/atvbaha.110.203604 |
| | Dabigatran-13C,d3 Preparation Products And Raw materials |
|